According to filings with the U.S. Securities and Exchange Commission, Cytonus Therapeutics is raising $21,603,089.00 in new funding. Sources indicate that as part of senior management President, Remo Moomiaie played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cytonus Therapeutics
At Cytonus, we think about drug delivery differently. Breaking away from current paradigm, the products at Cytonus are designed for precise homing to disease tissue and highly localized therapeutic activity. Our goal is to significantly improve patient outcomes while minimizing systemic toxicity or unintended side-effects. The Cargocyte platform at Cytonus has diverse applications as it can be engineered to target specific tissues and can deliver strategic therapeutic payloads. Cargocyte is an innovative cell-based drug transporter that can deliver therapeutics specifically to a disease site in the body. Cargocytes are administered systemically but act locally to optimize therapeutic outcomes and minimize toxicities or off-target effects. They can access difficult to treat tissues to address critical unmet needs for patients.

To learn more about Cytonus Therapeutics, visit http://cytonus.com/

Contact:
Remo Moomiaie, President
631-258-4070
https://www.linkedin.com/in/remo-moomiaie-qajar-m-d-7bb4835/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.